Bibliothèque Scientifique

📅 Publié le 22 April 2026

Les déterminants associés à la suppression de la charge virale chez les personnes vivant avec le VIH sous traitement à base de Dolutégravir Determinants of Viral Load Suppression in People Living with HIV on Dolutegravir-Based Treatment

Objectif : cette étude vise à évaluer l’efficacité du Dolutégravir (DTG) et à identifier les facteurs associés à la suppression de la charge virale chez les adultes vivant avec le VIH (PVVIH) suivis aux Cliniques Universitaires de Lubumbashi, en République Démocratique du Congo.

📥 Télécharger le document

📅 Publié le 22 April 2026

Knowledge, Attitudes, and Practices of Healthcare Workers Regarding Sepsis in Lubumbashi, Democratic Republic of the Congo

1. Introduction Sepsis is defined as a life-threatening syndrome associated with immune, endo crine, cardiovascular, and metabolic disturbances resulting from an extreme reac tion of the body to an infection, leading to organ failure and death if not treated promptly [1]-[5]. It is a major cause of morbidity and mortality in intensive care units (ICUs) worldwide [6]. In resource-limited countries, such as the Democratic Republic of the Congo (DRC), its management is complicated by inadequate heal- thcare infrastructure, a shortage of trained personnel, and limited access to treat ments. In Lubumbashi, the second-largest city in the country, the situation re mains concerning due to these constraints.

📥 Télécharger le document

📅 Publié le 22 April 2026

More TreatmentFailuresamongMale in a Prospective More TreatmentFailuresamongMale in a Prospective RandomizedNNRTI vs b-PI trial in Naïve HIV-1 infectedPatients in a Resource -Limited Setting (RLS)

•WHO recommends 1NNRTI + 2 NRTIsas first-line regimenin Resource-Baseline Characteristics : Female vsMale •WHO recommends 1NNRTI + 2 NRTIsas first-line regimenin Resource limitedcountries and boostedPI assecond line regimen n Female Baseline Characteristics : Female vsMale limitedcountries and boostedPI assecond line regimen • In RLSs cohortsstudieshave reportedworseclinicaland virological outcomesincludingdeathsin male comparedto female n Age (years), Median, Range 36 Female 305 outcomesincludingdeathsin male comparedto female • Lateaccessto care,differences in behavior and lower adherence to Age (years), Median, Range 36 Black, n (%) 305 Weight (kg), Median , Range 53 Body Mass Index(BMI),kg/m2,mean (range) 20 • Lateaccessto care,differences in behavior and lower adherence to therapyhave been advocatedto explainthesefindings • The week96 resultsofa prospective randomizedtrial comparingNVP Body Mass Index(BMI),kg/m2,mean (range) 20 OMS stage III, n (%) 280 OMS stage IV, n (%) 10 • The week96 resultsofa prospective randomizedtrial comparingNVP based regimensto LPV/r-basedregimensas first-line OMS stage IV, n (%) 10 Previous exposure to NVP single dose for PMTCT, n 3 therapyin Lubumbashi (Congo, DRC) showedmore virologicfailure(VL>1000c/ml) and more CD4 count (cell/µL)-Median (Range) 163 CD4 count < 100/µL 83 virologicfailure(VL>1000c/ml) and more Drug resistancemutations amongpatients on NVP patients (abstract#K-1001 CROI 2012) HIV RNA (log copies/ml),-Median, (range) 5,1 HIV RNA >100 000 copies/ml (%) 159 patients (abstract#K-1001 CROI 2012) • This isa report of gendersubanalysisof the stud

📥 Télécharger le document